<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-<z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et syndrome (ABS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS </plain></SENT>
<SENT sid="2" pm="."><plain>The duration of the disease ranged from 1 to 12 years </plain></SENT>
<SENT sid="3" pm="."><plain>Subcutaneous ABS injections in a dose 5 x 10(6) U/m2 for 8 weeks followed by 3 x 10(6) for 16 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>The results were estimated by standard clinical and biochemical indices </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> 18 patients responded to the treatment </plain></SENT>
<SENT sid="6" pm="."><plain>After the course of treatment 13 patients were in remission for 4-52 months </plain></SENT>
<SENT sid="7" pm="."><plain>The rest of the patients were given one more course of treatment </plain></SENT>
</text></document>